In this section : Covid-19
Molnupiravir
Sotrovimab
Conscious Proning
Covid-19 Basics
Remdesivir
Thromboprophylaxis
Identifying Patients in the Highest Risk Groups
Steroids for Patients with Covid-19 Infection
IL-6 Inhibitors – Tocilizumab or Sarilumab
Baricitinib
Paxlovid (Nirmatrelvir/Ritonavir)
Covid-19 Sick Day Rules for Patients with Primary Adrenal Insufficiency
Baricitinib
Last updated 27th June 2023
Please ensure you have read the information on the Covid-19 Basics page before proceeding.
Background
- Baricitinib does not have a product license for use in the treatment of COVID-19 and has therefore not been assessed by NICE or SMC for this indication.
- The RECOVERY trial showed positive results for patients treated with baricitinib, therefore it remains an option for use in patients who are not recovering despite treatment with other medications recommended by NICE/SMC.
- Please discuss with relevant consultant and pharmacist before prescribing.
- May be suitable for inpatients with COVID pneumonia who are not pregnant and have:
- New or increased oxygen requirement of any kind, due to COVID-19 infection.
- eGFR ≥ 15ml/min
- Neutrophils > 0.5 x 109/L
- No active tuberculosis
Dose
eGFR 60ml/min 1.73m2 or greater | 4mg daily |
eGFR 30-59ml/min 1.73m2 | 2mg daily |
eGFR 15-29ml/min 1.73m2 | 2mg alternate days |
- Treatment length is 10 days or until discharge, whichever is sooner.
Links
- SEHD Covid Therapeutic Alert 2023 1 – Publication of NICE Multiple Technology Appraisal (MTA) – Treatment Recommendations for Covid 19
- RECOVERY Trial Result: Baricitinib reduces deaths in patients hospitalised with Covid-19
Content by Alison Moore